CVE-2022-24811

Public Exploit
Cross-site Scripting in Combodo iTop

Description

Combodi iTop is a web based IT Service Management tool. Prior to versions 2.7.6 and 3.0.0, cross-site scripting is possible for scripts outside of script tags when displaying HTML attachments. This issue is fixed in versions 2.7.6 and 3.0.0. There are currently no known workarounds.

Category

5.4
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.29%
Third-Party Advisory github.com Third-Party Advisory github.com Third-Party Advisory huntr.dev
Affected: Combodo iTop
Published at:
Updated at:

References

Link Tags
https://github.com/Combodo/iTop/security/advisories/GHSA-67x5-mqg4-rvgc third party advisory
https://github.com/Combodo/iTop/commit/92a9a8c65f3cbb2cd4414ca3a3b45a5754ba57b4 third party advisory patch
https://huntr.dev/bounties/1625056478879-Combodo/iTop/ third party advisory exploit

Frequently Asked Questions

What is the severity of CVE-2022-24811?
CVE-2022-24811 has been scored as a medium severity vulnerability.
How to fix CVE-2022-24811?
To fix CVE-2022-24811, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-24811 being actively exploited in the wild?
It is possible that CVE-2022-24811 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-24811?
CVE-2022-24811 affects Combodo iTop.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.